Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAPKEY: Pembrolizumab in classic or endemic Kaposi's sarcoma
2016-003714-27Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Kaposi sarcoma (KS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Best Overall Response Rate (BORR). Started Sep 2024; status: active.
02
Drugs
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on 2016-003714-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003714-27.